Differences in Salivary Flow Level, Xerostomia, and Flavor Alteration in Mexican HIV Patients Who Did or Did Not Receive Antiretroviral Therapy

Table 3

Inter- and intragroup comparisons of years of antiretroviral therapy and salivary flow.

HAART years	Mean and standard deviation	Significance
1–3	43.4 ± 23.5	0.000^♣
4–6	29.9 ± 20.1
7–10	30.8 ± 15.9
>11	23.4 ± 15.5
	Mean and standard deviation	Significance
1–3
4–6	13.5 ± 4.0	0.006^◆
7–10	12.6 ± 4.5	0.048^◆
>11	20.0 ± 4.5	0.000^◆
4–6
1–3	−13.5 ± 4.0	0.006^◆
7–10	−0.9 ± 4.7	1.000^◆
>11	6.5 ± 4.7	0.673^◆
7–10
1–3	−12.6 ± 5.4	0.048^◆
4–6	0.9 ± 4.7	1.000^◆
>11	7.4 ± 5.1	0.634^◆
>11
1–3	−20.6 ± 4.5	0.000^◆
4–6	−6.4 ± 4.7	0.673^◆
7–10	−7.4 ± 5.1	0.634^◆

Resource: Civil Hospital “Fray Antonio Alcalde” HIV Unit.
♣One-way ANOVA; confidence interval percentage of 95%.
◆Post hoc testing: Dunnett’s T3.